Kyoto-based xFOREST Therapeutics and Kanagawa-based Axcelead Drug Discovery Partners, Inc. have launched a joint research collaboration to develop RNA structure-targeted small molecule therapeutics for multiple diseases. This partnership aims to strengthen a new drug discovery platform by combining their respective expertise. Therapeutics and Kanagawa-based Axcelead Drug Discovery Partners, Inc. have launched a joint research collaboration to develop RNA structure-targeted small molecule therapeutics for multiple diseases. This partnership aims to strengthen a new drug discovery platform by combining their respective expertise.

xFOREST brings its proprietary "FOREST Technologies," a platform specializing in identifying small molecule compounds that can target RNA structures, which were previously considered "undruggable" with traditional methods. Axcelead DDP, a comprehensive drug discovery solutions provider with a background from Takeda Pharmaceutical, is investing in this next-generation modality and brings its integrated research platform and extensive experience to the collaboration. The goal of this joint effort is to enhance research efficiency and increase the probability of generating viable drug candidates. Under the terms of the agreement, xFOREST will retain the exclusive rights to develop and commercialize any selected compounds. In return, Axcelead DDP will be entitled to milestone payments, which incentivizes them to contribute their expertise and technology to the partnership.

Leaders from both companies expressed excitement about the collaboration, highlighting the potential to accelerate the development of innovative, RNA-targeted treatments and provide new therapeutic options to patients as quickly as possible.